At ILIAS Biologics, we dedicate ourselves to the development of paradigm-shifting advances in human medicine. Exosomes, extracellular vesicles naturally released by cells, represent such an opportunity thanks to its unique ability to deliver biological information between cells.
Our platform technology, EXPLOR™, makes it possible to load large therapeutic molecules into exosomes, and we are actively developing various therapeutic exosomes, Exo-Targets®, as potential treatments for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory and metabolic areas.

With a strong belief in the power of open innovation, we are expanding our global network of research and business alliances. ILIAS Therapeutics, Inc. in the U.S. plays a key role in facilitating our relationships with alliance partners.